Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2009-8-21
pubmed:abstractText
Hypoxia-inducible factor 1 (HIF-1) plays essential roles in tumor angiogenesis and growth by regulating the transcription of several key genes in response to hypoxic stress and growth factors. HIF-1 is a heterodimeric transcriptional activator consisting of inducible alpha and constitutive beta subunits. In oxygenated cells, proteins containing the prolyl hydroxylase domain (PHD) directly sense intracellular oxygen concentrations. PHDs tag HIF-1alpha subunits for polyubiquitination and proteasomal degradation by prolyl hydroxylation using 2-oxoglutarate (2-OX) and dioxygen. Our recent studies showed that 2-OX reduces HIF-1alpha, erythropoietin, and vascular endothelial growth factor (VEGF) expression in the hepatoma cell line Hep3B when under hypoxic conditions in vitro. Here, we report that similar results were obtained in Lewis lung cancer (LLC) cells in in vitro studies. Furthermore, 2-OX showed potent antitumor effects in a mouse dorsal air sac assay and a murine tumor xenograft model. In the dorsal air sac assay, 2-OX reduced the numbers of newly formed vessels induced by LLC cells. In a murine tumor xenograft model, intraperitoneal injection of 2-OX significantly inhibited tumor growth and angiogenesis in tumor tissues. Moreover, 5-fluorouracil combined with 2-OX significantly inhibited tumor growth in this model, which was accompanied by reduction of Vegf gene expression and inhibited angiogenesis in tumor tissues. These results suggest that 2-OX is a promising anti-angiogenic therapeutic agent.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1349-7006
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1639-47
pubmed:meshHeading
pubmed-meshheading:19575748-Angiogenesis Inhibitors, pubmed-meshheading:19575748-Animals, pubmed-meshheading:19575748-Blotting, Western, pubmed-meshheading:19575748-Carcinoma, Lewis Lung, pubmed-meshheading:19575748-Cell Proliferation, pubmed-meshheading:19575748-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:19575748-Flow Cytometry, pubmed-meshheading:19575748-Fluorouracil, pubmed-meshheading:19575748-Humans, pubmed-meshheading:19575748-Hypoxia-Inducible Factor 1, alpha Subunit, pubmed-meshheading:19575748-Immunoenzyme Techniques, pubmed-meshheading:19575748-Ketoglutaric Acids, pubmed-meshheading:19575748-Male, pubmed-meshheading:19575748-Melanoma, Experimental, pubmed-meshheading:19575748-Mice, pubmed-meshheading:19575748-Mice, Inbred C57BL, pubmed-meshheading:19575748-Neovascularization, Pathologic, pubmed-meshheading:19575748-RNA, Messenger, pubmed-meshheading:19575748-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:19575748-Tumor Cells, Cultured, pubmed-meshheading:19575748-Vascular Endothelial Growth Factor A, pubmed-meshheading:19575748-Xenograft Model Antitumor Assays
pubmed:year
2009
pubmed:articleTitle
Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model.
pubmed:affiliation
Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. c0630210@md.tsukuba.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't